figshare
Browse

Brad Blaser

Publications

  • Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
  • Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation
  • Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity
  • Generation of Parabiotic Zebrafish Embryos by Surgical Fusion of Developing Blastulae
  • Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder
  • A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia
  • Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells
  • STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo
  • CXCR1 remodels the vascular niche to promote hematopoietic stem and progenitor cell engraftment
  • The PP2A inhibitor SET regulates natural killer cell IFN-gamma production
  • IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease
  • Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia
  • FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
  • The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
  • New directions in natural killer cell-based immunotherapy of human cancer
  • Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35
  • Tumor growth impedes natural-killer-cell maturation in the bone marrow
  • Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease
  • Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
  • Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15
  • A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation
  • In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis
  • Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells
  • Resistance to PRMT5-targeted therapy in mantle cell lymphoma
  • Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
  • An Optimized Zebrafish Nursery Feeding Regimen Improves Growth Rates and Labor Costs
  • Making HSCs in vitro: Don’t forget the hemogenic endothelium
  • Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative Amplicon Barcodes
  • Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
  • Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
  • CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival
  • Microenvironmental control of hematopoietic stem cell fate via CXCL8 and protein kinase C
  • A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
  • BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
  • CD200 promotes immunosuppression in the pancreatic tumor microenvironment

Brad Blaser's public data